Lifeblood Medical receives U.S. patent notice

Lifeblood Medical has announced that it has received a Notice of Allowance from the U.S. Patent Office for its patent application titled, "Composition for Maintaining Organ and Cell Viability."

The allowed claim provides patent protection for Lifeblood's proprietary solutions related to the prolonged preservation of organs, tissues and cells, and particularly for the preservation of organs donated for transplantation, as well as methods of making and using the same.

"We are extremely pleased with the allowance of our first patent," stated Joseph Fischer, President and Chief Executive Officer of Lifeblood Medical, Inc. "This patent, once issued, will provide Lifeblood with significant intellectual property protection to support Lifor(R) for FDA approval for heart preservation and transportation. We also have additional pending U.S. patent applications directed to other aspects of the technology including related compositions, method of making and using the proprietary solutions and the Lifor(R) technology for preservation and transportation of a multitude of organs, cells and tissues."